Clinical Development in Japan
Your Trusted Partner in Japan, the second largest branded pharmaceutical market


Since December 2023, the Ministry of Health, Labor and Welfare (MHLW) has introduced regulatory changes aimed at eliminating Japan's drug lag and loss. This fact sheet provides a concise summary of these recent regulatory updates in Japan. The IQVIA Japan regulatory consulting team, with its extensive experience in PMDA consultations, is ready to support and discuss clinical development in Japan.
Your Trusted Partner in Japan, the second largest branded pharmaceutical market